CLNP023E12201: PoC study of Iptacopan in early & intermediate age-related macular degeneration (AMD)
Research type
Research Study
Full title
A randomized, participant and investigator masked, placebo-controlled, multicenter, proof-of-concept study to assess the safety and efficacy of LNP023 (Iptacopan) in patients with early and intermediate age-related macular degeneration
IRAS ID
1007087
Contact name
Florent Revel
Contact email
Sponsor organisation
Novartis Pharma AG
Eudract number
2021-001797-31
Clinicaltrials.gov Identifier
Research summary
This is a study in participants with an eye disease called age-related macular degeneration (AMD). The purpose of the study is to find out if a medicine named Iptacopan can preserve vision by stopping the progression of the early and intermediate stages of the disease to the late stage of AMD. People can participate if they are at least 50 years old and if one eye is diagnosed with early or intermediate AMD and the other is treated with anti-VEGF therapy for wet (neovascular) AMD. During the study, participants will take by mouth (orally) Iptacopan or a placebo (sugar pill) every day for 29 months. During the entire study, doctors regularly check the overall health and eye condition of the participants.
REC name
North of Scotland Research Ethics Committee 1
REC reference
23/NS/0072
Date of REC Opinion
1 Sep 2023
REC opinion
Further Information Favourable Opinion